Amylyx Pharmaceuticals shares fall after ALS treatment is rejected by European regulatorMarket Watch • 10/13/23
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination ProcessBusiness Wire • 10/13/23
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial ControlBusiness Wire • 10/10/23
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in FranceBusiness Wire • 10/05/23
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) MeetingBusiness Wire • 10/02/23
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/10/23
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023Business Wire • 08/03/23
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) ProgramBusiness Wire • 07/12/23
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European UnionBusiness Wire • 06/23/23
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALSBusiness Wire • 06/15/23
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 06/06/23
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European UnionBusiness Wire • 05/30/23